Metformin intake associates with better cognitive function in patients with Huntington's disease

Huntington's disease (HD) is an inherited, dominant neurodegenerative disorder caused by an abnormal expansion of CAG triplets in the huntingtin gene (htt). Despite extensive efforts to modify the progression of HD thus far only symptomatic treatment is available. Recent work suggests that trea...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2017-06, Vol.12 (6), p.e0179283
Main Authors: Hervás, David, Fornés-Ferrer, Victoria, Gómez-Escribano, Ana Pilar, Sequedo, María Dolores, Peiró, Carmen, Millán, José María, Vázquez-Manrique, Rafael P
Format: Article
Language:English
Subjects:
Adult
Aged
Analysis
Animal models
Antidiabetics
Apoptosis
Biology and Life Sciences
Case-Control Studies
Cognition - drug effects
Cognition - physiology
Cognitive ability
Complications and side effects
Cross-Sectional Studies
Diabetes
Diabetes mellitus
Dosage and administration
Drug therapy
Female
Genetic aspects
Heart attacks
Hereditary diseases
Humans
Huntingtin
Huntington Disease - drug therapy
Huntington's disease
Huntingtons disease
Hypoglycemic Agents - therapeutic use
Insulin
Kinases
Male
Medical research
Medicine and Health Sciences
Metformin
Metformin - therapeutic use
Middle Aged
Neurodegenerative diseases
Neurons
Observational studies
Pathology
Patients
Polyglutamine
Population (statistical)
Proteins
Research and Analysis Methods
Statistical analysis
Substance abuse treatment
Trinucleotide repeats
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Huntington's disease (HD) is an inherited, dominant neurodegenerative disorder caused by an abnormal expansion of CAG triplets in the huntingtin gene (htt). Despite extensive efforts to modify the progression of HD thus far only symptomatic treatment is available. Recent work suggests that treating invertebrate and mice HD models with metformin, a well-known AMPK activator which is used worldwide to treat type 2-diabetes, reduces mutant huntingtin from cells and alleviates many of the phenotypes associated to HD. Herein we report statistical analyses of a sample population of participants in the Enroll-HD database, a world-wide observational study on HD, to assess the effect of metformin intake in HD patients respect to cognitive status using linear models. This cross-sectional study shows for the first time that the use of metformin associates with better cognitive function in HD patients.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0179283